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ABSTRACT 
A biodegradable electroactive material can be doped with a 
drug and the drug can be delivered to a living subject by 
stimulating the material with an electrical potential . The 
material ( in this case a polymer ) has an electrochemically 
responsive oligoaniline block terminated with a carboxylic 
acid moiety and is linked to an alcohol - terminated diol by an 
ester bond . Advantageously , the diol is PEG - 400 , PEG 
2000 , PCL - 530 , or PCL - 2000 . 
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Higure 10 . A ) Experimental setup : Pt mesh counter electrode ( CE ) , AgAgCl reference electrode 
( RE ) , DMP - doped polymer film coated on a glassy carbon working electrode ( WE ) . B ) Electrical 
stimolation paradigm . C ) Release of DMP ( rom films of 1 - O PBS : with slectrical stimulation 
( sold buns ) or without electrical stimulation ( checked bars ) . I red . 2 ) blue . 3 ) green . 4 ) porple . 
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Figure 11 . A ) Experimental setup . counter elecinde ( CE ) , reference electrixie ( RE ) , working 
electrode ( WB ) . B ) Electrical stimulation paradigm . C ) Release of DMP fron filmis of 1 in 
PBS : with electrical stimulation ( solid bars ) or without electrical stimulation ( checked bars ) . 1 ) 
red . 2 ) blue . 3 ) green . 4 ) purple . 
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DRUG DELIVERY USING ferred embodiments , X is poly ( ethylene glycol ) s having 
ELECTROCHEMICALLY - TRIGGERED average molecular weight of 400 Da . ( PEG - 400 ) , poly 
BIODEGRADABLE ELECTROACTIVE ( ethylene glycol ) s having average molecular weight of 2000 
MATERIALS Da . ( PEG - 2000 ) , poly ( caprolactone ) s having average 
5 molecular weight of 530 Da . ( PCL - 530 ) or poly ( caprolac 
BACKGROUND OF THE INVENTION tone ) s having average molecular weight of 2000 Da . ( PCL 
2000 ) . 
The invention relates to electroactive materials , and more To deliver a drug to a living subject , in a method accord 
particularly relates to biodegradable electroactive materials ing to the invention an electroactive material in accordance 
( some of which conduct electricity ) . In its most immediate 10 with the invention is doped with the drug to be delivered and 
sense , the invention relates to biodegradable electroactive the doped material is stimulated by application of an elec 
materials that can be used for delivering drugs to living trical potential . Camphorsulfonic acid can be used as a 
subjects . dopant to promote the adhesion of C6 cells , keratinocytes , 
Researchers have investigated the use of electroactive MC3T3 - E1 cells , osteoblasts , PC12 cells , Schwann cells , 
polymers as drug delivery agents . A literature review ( D . 15 human Mesenchymal stem cells , human dermal fibroblasts 
Svirskis , J . Travas - Sejdic , A . Rodgers , S . Garg , J . Control and potentially others . Dexamethasone phosphate can be 
Rel . 2010 , 146 , 6 ) discusses delivery of adenosine triphos - used as a dopant in instances wherein the invention is used 
phate , dexamethasone phosphate , DNA , dopamine , nerve to deliver it to a living subject in order to utilize its 
growth factor , and N - methylphenothiazine . However , the anti - inflammatory properties . 
electroactive polymers used to deliver these drugs are not 20 
fully biodegradable . And , while some biodegradable elec BRIEF DESCRIPTION OF THE DRAWINGS 
troactive polymers are known ( T . J . Rivers , T . W . Hudson , C . 
E . Schmidt , Adv . Funct . Mater . 2002 , 12 , 33 ) they are The invention will be better understood with reference to 
unsuitable for use in drug delivery systems because they the following illustrative and non - limiting drawings , in 
only become electroactive after being oxidized using iodine , 25 which : 
and iodine is toxic . FIG . 1 shows the synthesis of carboxylic acid - terminated 
It would be advantageous to provide a fully biodegradable aniline pentamers used to synthesize the preferred embodi 
electroactive material that could be used to deliver a drug to ments of the invention ; 
a living subject without requiring use of an oxidizer such as FIG . 2 shows the structure of a first preferred embodiment 
iodine . 30 of the invention , using PEG - 400 ; 
FIG . 3 shows the synthesis of the first and second pre 
SUMMARY OF THE INVENTION ferred embodiments of the invention ; 
FIG . 4 shows the structure of a second preferred embodi 
In accordance with the invention , there are provided fully ment of the invention , using PEG - 2000 ; 
biodegradable electroactive materials from which drug 35 FIG . 5 shows the structure of a third preferred embodi delivery can be triggered electrochemically . ment of the invention , using PCL - 530 ; 
The invention proceeds from the realization that water FIG . 6 shows the synthesis of the third and fourth pre 
soluble electrochemically responsive units ( e . g . , oligoani - ferred embodiments of the invention ; 
lines , oligothiophenes , polypyrrole , various monomers , fer FIG . 7 shows the structure of a fourth preferred embodi 
rocene , porphyrin ) are an essential characteristic for delivery 40 ment of the invention , using PCL - 2000 ; 
of a drug to a living subject from fully degradable materials . FIG . 8 shows the structure of camphorsulfonic acid ; 
By linking water - soluble electrochemically responsive units FIG . 9 shows the structure of dexamethasone phosphate ; ( particularly carboxylic acid - terminated oligoaniline blocks ) FIG . 10 schematically illustrates an experiment to mea 
to other units ( particularly alcohol - terminated diols , includ - sure delivery of dexamethasone phosphate in a context 
ing alcohol - terminated blocks of either polyethylene glycol 45 similar to use of an implant to stimulate the central nervous ( PEG ) or polycaprolactone ( PCL ) ) using biodegradable system wherein tissue surrounding the implant is used as a 
bonds , particularly ester bonds , biodegradable electroactive counter electrode ; 
materials ( particularly polymers ) are formed . When electro - FIG . 11 schematically illustrates an experiment to mea 
chemically responsive units are “ doped ” with a drug , drug sure delivery of dexamethasone phosphate in a context 
delivery can be triggered by application of an electrical 50 similar to powering a conductive tissue scaffold . 
potential . Furthermore , as long as the molecular weight of 
the units is smaller than the 70 kDa renal filtration threshold , DETAILED DESCRIPTION OF PREFERRED 
the kidney can remove the degradation products of the EMBODIMENTS 
inventive materials from the bloodstream . 
In accordance with the invention , an electroactive mate - 55 Preferred embodiments of the invention were produced by 
rial comprises a water soluble electrochemically responsive esterification of aniline pentamers terminated with carbox 
unit linked to another unit by a biodegradable bond , with the ylic - acids . Production of the aniline pentamers will be 
molecular weight of the units being smaller than the renal discussed initially ; synthesis of the preferred embodiments 
filtration threshold . Advantageously , the material is a poly - will be discussed afterward . 
mer . Preferred embodiments of the invention are of the form 60 
A . Production of Precursor Aniline Pentamers 
0 0 ] Hoc HHO + X - Ont fotx - ost Referring first to FIG . 1 , the synthesis of the carboxylic acid - terminated aniline pentamers was adapted from a 65 known method ( L . Chen , Y . Yu , H . Mao , X . Lu , W . Zhang , 
Y . Wei , Chem . J . Chin . Univ . 2004 , 25 ( 9 ) , 1768 - 1770 ) . 
N - phenyl - 1 , 4 - phenylenediamine ( 9 . 2 g , 50 mmol ) and suc 
wherein X is polyethylene glycol ( PEG ) or polycaprolactone 
( PCL ) . Advantageously , and in accordance with the pre - 
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cinic anhydride ( 5 . 0 g , 50 mmol ) were dissolved in dichlo - dispersed in chloroform ( 10 mL ) , after which it was re 
romethane ( DCM , 300 mL ) and stirred overnight at room precipitated in diethyl ether , and this process of resuspension 
temperature . The product was isolated by filtration , washed in chloroform followed by re - precipitation in diethyl ether 
with diethyl ether until the diethyl ether was clear and was repeated two more times . The resulting polymers were 
colorless , and dried under vacuum for 24 hours , yielding 5 dried under high vacuum for 24 hours . The polymers could 
12 . 0 g ( 42 mmol , 84 % yield ) of blue - gray solid ( a succinic be reduced to the leucoemeraldine state via brief exposure to 
acid - capped aniline dimer ) . This blue - gray solid ( 2 . 9 g , 10 aqueous hydrazine for ca . 15 minutes ( after which no further 
mmol ) and p - phenylenediamine ( 0 . 54 g , 5 mmol ) were gas was observed to evolve ) followed by dialysis against dissolved in dimethylformamide ( DMF , 15 mL ) and the ultrapure water in a cellulose dialysis tube with a molecular 
solution cooled to 0° C . on ice . A cooled solution of DMF 10 weight cutoff of ca . 3 , 500 Da , and dried under high vacuum ( 30 mL ) , water ( 25 mL ) and concentrated hydrochloric acid for 48 hours . ( 5 mL ) was added . A solution of ammonium persulfate ( 2 . 28 
g , 10 mmol ) in aqueous hydrochloric acid solution ( 50 mL , C . Synthesis of the First Preferred Embodiment of 1 M ) was added slowly and the reaction mixture stirred the Invention quickly for 1 hour at 0° C . After this time the reaction 15 
mixture was added to water ( 300 mL ) resulting in the The first preferred embodiment of the invention ( FIG . 2 ) precipitation of a solid , which was isolated by filtration . The was synthesized using poly ( ethylene glycol ) with an average product was reduced by stirring a suspension of the product molecular weight of 400 Da . The synthesis is shown in FIG . in aqueous ammonia ( 300 mL , 1 M ) overnight , after which 3 . 1 . 6 g of the first preferred embodiment was isolated via the pH was lowered to 2 - 3 by addition of aqueous hydro - 20 this procedure , in a yield of 50 % by mass . 
chloric acid ( 1 M ) , and the product isolated by filtration . The 
product was dried under vacuum at 45° C . for 48 hours . A D . Synthesis of the Second Preferred Embodiment 
solution of the crude product ( 3 . 0 g ) in DMF ( 15 mL ) was of the Invention 
slowly added to ethanol ( 150 mL ) resulting in the precipi 
tation of a solid material that was isolated by filtration and 25 The second preferred embodiment of the invention ( FIG . 
dried under vacuum . The product was purified by Soxhlet 4 ) was synthesized using the same synthesis as was used to 
extraction with 1 , 2 - dichloroethane followed by THF . The produce the first preferred embodiment , except that using 
succinic acid - capped aniline pentamer ( AP at the bottom of alcohol - terminated poly ( ethylene glycol ) s with an average 
FIG . 1 ) was dried under vacuum for 48 hours , after which molecular weight of 2 , 000 Da . were used . 4 . 25 g of the 
1 . 8 g ( 2 . 7 mmol , 54 % yield ) was isolated in an analytically 30 second preferred embodiment was isolated via this proce 
pure form in accordance with the literature . dure , in a yield of 53 % by mass . 
B . General Methodology for Synthesizing the 
Preferred Embodiments 
E . Synthesis of the Third Preferred Embodiment of 
the Invention 
35 
The preferred embodiments of the inventions described The third preferred embodiment of the invention ( FIG . 5 ) 
herein are all polymers , but it will be understood that this is was synthesized using the synthesis illustrated in FIG . 6 , 
only preferred and that materials in accordance with the using poly ( caprolactone ) diol with an average molecular 
invention need not be polymeric ; diols need not necessarily weight of 530 Da . 2 . 2 g of the third preferred embodiment 
be employed and other biodegradable bonds can be used to 40 was isolated via this procedure , in a yield of 62 % by mass . 
link to the water soluble electrochemically responsive units . 
The type of biodegradable bond employed will be deter F . Synthesis of the Fourth Preferred Embodiment of 
mined by the type of blocks that are bonded together . the Invention 
Furthermore , it will be understood that although the pre 
ferred embodiments described herein use carboxylic acid - 45 The fourth preferred embodiment of the invention ( FIG . 
terminated oligoaniline blocks as the electrochemically 7 ) was synthesized using the same synthesis used for the 
responsive units , other water soluble electrochemically third preferred embodiment , except that poly ( caprolactone ) 
responsive units can be used instead . The herein - described diol with an average molecular weight of 2 , 000 Da . was 
preferred embodiments were produced by a synthesis employed . 1 . 0 g of the fourth preferred embodiment was 
adapted from a known method ( L . Huang , J . Hu , L . Lang , X . 50 isolated via this procedure , in a yield of 25 % by mass . 
Wang , P . Zhang , X . Jing , X . Wang , X . Chen , P . I . Lelkes , A . 
G . MacDiarmid , Y . Wei , Biomaterials 2007 , 28 , 1741 ) . In G . Doping of the Preferred Embodiments and Drug 
short , alcohol - terminated poly ( ethylene glycol ) s or poly Delivery 
( caprolactone ) s ( 3 mmol ) were dissolved in N - methyl - 2 
pyrrolidone ( NMP , 20 mL ) , to which was added AP ( 2 . 0 g , 55 Advantageously , electroactive materials in accordance 
3 . 0 mmol ) , dicyclohexylcarbodiimide ( DCC , 1 . 9 g , 9 . 0 with the invention can be doped . One suitable dopant is 
mmol ) and 4 - dimethylaminopyridine ( DMAP , 0 . 2 g , 2 . 0 camphorsulfonic acid ( FIG . 8 ) , which can promote adhesion 
mmol ) . The reaction mixture was stirred at room tempera - ofe . g . C6 cells , keratinocytes , MC3T3 - El cells , osteoblasts , 
ture under an inert atmosphere of argon . After 72 hours the PC12 cells , Schwann cells , human Mesenchymal stem cells , 
reaction mixture was filtered and added drop - wise to diethyl 60 human dermal fibroblasts and potentially others . Alterna 
ether ( 1 . 5 L ) that was stirred to assure the precipitation of a tively , the dopant can be the drug to be delivered to the living 
fine powder of the respective polymer . The stir bar was subject . Where for example it is necessary to treat inflam 
removed and the product was allowed to settle to the bottom mation , the dopant can be dexamethasone phosphate ( FIG . 
of the container ( typically 15 - 30 minutes ) . The diethyl ether 9 ) , which has anti - inflammatory properties . 
was removed via pipette suction , and the polymer - rich layer 65 The ability of electroactive materials in accordance with 
at the bottom of the container was concentrated with a rotary the invention to deliver a drug to a living subject was 
evaporator to yield a thick oil . The oil was dissolved / demonstrated using dexamethasone phosphate ( DMP ) , an 
US 9 , 783 , 637 B2 
111 ) . 
anti - inflammatory having a molecular weight of 490 Da . observed to decrease very slowly over a week , and the 
Release of DMP into phosphate buffered saline ( PBS ) solu presence of the esterase moderately increased the rate at 
tion was monitored using UV spectroscopy . Films composed which this occurs . It was consequently concluded that the 
of each of the first , second , third , and fourth preferred films would degrade slowly if administered in vivo ( over the 
embodiments and approximately 3 to 4 mg DMP were 5 period of weeks to months ) . Analogous CSA - doped mate 
prepared on bioinert conductive and non - conductive sub - rials have been shown to support the adhesion of a variety 
strates ( glassy carbon electrodes and glass , respectively ) . of cells including C6 cells , keratinocytes , MC3T3 - E1 cells , 
DMP loadings were at a mole ratio of 1 : 1 dexamethasone osteoblasts , PC12 cells and Schwann cells , human Mesen 
phosphate : aniline pentamers ( approximately 31 wt % for chymal stem cells , and human dermal fibroblasts . Films of 
the first and third preferred embodiments and approximately 10 the first and third preferred embodiments were found to be 
16 wt % for the second and fourth preferred embodiment ) . prone to fracture as a consequence of exposure to dynamic 
The experimental setups are depicted in FIGS . 10 and 11 . shear forces encountered during multiple media changes at 
The setup depicted in FIG . 10A ( using films deposited on 37° C . Films of the second and fourth preferred embodi 
glassy carbon substrates ) is akin to that used for electrodes ments were much more robust and both human dermal 
implanted for stimulation of the central nervous system in 15 fibroblasts and human mesenchymal stem cells were seen 
which the tissue surrounding the implant is used as a counter adhered to the films , suggesting their potential for in vivo 
electrode . The setup depicted in FIG . 11A ( using films implantation for a variety of applications ( e . g . , drug eluting 
deposited on glass substrates ) is a simple closed circuit coatings on completely biodegradable implants ) . 
similar to those proposed to power some conductive tissue Electrically triggered drug release from materials in 
scaffolds . 20 accordance with the invention provides a novel platform for 
Pulsatile release of DMP from films deposited on glassy drug delivery . Synthesis and purification of polymers in 
carbon substrates was studied by chronoamperometry using accordance with the preferred embodiments is simple and 
1 minute of electrical stimulation followed by 14 minutes of scalable , requiring only 3 steps from commercially available 
rest ( FIG . 10B ) after which the quantity of DMP in the PBS starting materials . Polymers in accordance with the pre 
solution was quantified by UV spectroscopy . The medium 25 ferred embodiments are solution processable , thus facilitat 
was unchanged between cycles . The data are reported as ing the preparation of materials with a high drug loading of 
cumulative release as a percentage of the total mass of drug 16 or 31 wt % . Although DMP was used as a clinically 
in the film and compared to DMP release from unstimulated applied model drug , this was only for purposes of illustration 
films . Voltammetry scans and chronoamperometry pulses and other biologically - active molecules could be delivered 
were always initiated at the open circuit potential of the 30 instead , using the stimulation paradigms described here or 
system . Potential cycling was carried out between 0 . 7 V and others . Persons of ordinary skill in the art could modulate the 
- 0 . 5 V , first sweeping in the positive direction of the release profiles of these molecules via simple modifications 
potential scale at 50 mV s - . of the electrical input . Materials in accordance with the 
Passive release of DMP from unstimulated films was low invention have potential to be used for the manufacture of 
over the course of the experiment ( 1 . 5 hours ) , approximately 35 completely biodegradable drug delivery systems . 
8 % for the first preferred embodiment , approximately 3 % If non - polymeric electrochemically responsive units are 
for the second preferred embodiment , and approximately used instead of polymers , those units will not necessarily 
2 % for the third and fourth preferred embodiments ( FIG . display two alcohol functional groups . Rather , other units 
10C ) . Over a period of 24 days this increased to approxi - could be substituted for diols . As long as those other units 
mately 83 % for the first and second preferred embodiments , 40 are capable of being chemically bonded to the electrochemi 
approximately 48 % for the third preferred embodiment , and cally responsive unit ( if e . g . the other unit is an aldehyde , the 
approximately 35 % for the fourth preferred embodiment . In electrochemically responsive unit will be terminated with an 
contrast , electrochemically - triggered release of the drugs by oxyamine and the bond will be an oxime bond ) they need 
potential cycling ( FIG . 10C ) resulted in the release of only be degradable to units that are water soluble and have 
approximately 20 to 65 % of the drug during the initial cycle . 45 molecular weights that are below the renal filtration limit . 
Subsequent cycles were observed to release 5 to 10 % per Although preferred embodiments have been described 
cycle for the first six cycles , after which the majority of the above , the scope of the invention is limited only by the 
drug had been released from all of the films . following claims : 
The electrochemically - triggered release of DMP from 
films deposited on glass substrates ( FIG . 11A ) was studied . 50 The invention claimed is : 
A potential step of + 0 . 6 V was applied to each film for 30 1 . A method of delivering a drug to a living patient , 
seconds , followed by 29 . 5 minutes of rest ( FIG . 11B ) after comprising : implanting a doped biodegradable electroactive 
which the quantity of DMP in solution was quantified by UV polymer in the patient ; and stimulating the doped polymer 
spectroscopy . The first stimulation released 5 to 25 % of the by application of an electrical potential to the polymer , 
drug from the films ( FIG . 10C ) , the first and second stimu - 55 wherein stimulating the doped polymer causes delivery of 
lation released 25 to 50 % , and the third stimulation released the drug to the patient , 
between 50 to 90 % of the drugs from the films , all of which wherein the biodegradable electroactive polymer includ 
are clearly distinguishable from the passive release profiles . ing a water soluble electrochemically responsive unit 
linked to another unit by a biodegradable bond , and the 
H . Biodegradability drug , wherein the biodegradable electroactive polymer 
is of the form : 
To demonstrate the susceptibility of the materials in 
accordance with the invention to hydrolytic degradation in 
vitro , films of each of the preferred embodiments were - 
incubated in PBS in the absence or presence of cholesterol 65 l 
esterase ( 4 units / mL ) which is an enzyme known to hydro 
lyze ester bonds in polyesters . The mass of each film was wherein X is polyethylene glycol or polycaprolactone . 
60 
- ?????? 
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2 . The method of claim 1 , wherein each of the units has 
a molecular weight less than the renal filtration threshold . 
3 . The method of claim 1 , wherein X is : 
poly ( ethylene glycol ) s having average molecular weight 
of 400 Da . ; or poly ( ethylene glycol ) s having average molecular weight 
of 2000 Da . 
4 . The method of claim 1 , wherein X is : 
poly ( caprolactone ) s having average molecular weight of 
530 Da . ; or 
poly ( caprolactone ) s having average molecular weight of 
2000 Da . 
5 . The method of claim 1 , wherein the drug is dexam 
ethasone phosphate . 
10 
15 
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